Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|May 1, 2008
- Volume 0 0
Motion Sickness: Calming the Waves of Upset
Author(s)Yvette C. Terrie, BSPharm, RPh
Motion sickness is a common and inconvenient malady. Pharmacists can assist patients by counseling them on the proper use of pharmacologic agents commonly used to prevent and treat this condition and any adverse effects associated with the use of these agents. Nonpharmacologic approaches to managing this condition are also discussed.
Advertisement
Articles in this issue
over 18 years ago
advertiserINDEXover 18 years ago
productHOTLINEover 18 years ago
pharmacy Pet Peevesover 18 years ago
recruitment/RESOURCESover 18 years ago
canyouREADtheseRxs?over 18 years ago
Case Studiesover 18 years ago
DIABETESWATCHover 18 years ago
CHOLESTEROLWATCHover 18 years ago
compoundingHOTLINEover 18 years ago
ARTHRITISWATCHAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
4
New Data Reshape Nonstatin Lipid Therapy Choices
5